BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Introduces Symbiosis: an AI-Driven Operating Model to Align Business Priorities and AI-Accelerated Delivery14.10.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014833053/en/ Reply introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. As AI enables teams to develop, test and deliver solutions faster, organisations also need to adapt how they decide where to focus that cap
SIAL Paris 2026: Food Sovereignty, AI, Personalised Nutrition… Three Major Debates to Shape the Future of Food14.10.2026 09:35:00 CEST | Press release
More than just a major business event, SIAL Paris is also a forum for reflection, analysis and inspiration for the entire food sector. Over five days, several stages will bring together leaders, experts, manufacturers, retailers, researchers and entrepreneurs to analyse the sector’s transformations and, above all, to identify concrete courses of action. Food sovereignty, artificial intelligence, geopolitics, new consumption models, personalised nutrition and the transformation of the value chain: the 2026 edition offers a particularly rich programme, featuring conferences, keynote speeches, round-table discussions, pitches and case studies. SIAL Summits: three major events to understand today and prepare for tomorrow At the heart of this programme, the SIAL Summits, held in Hall 5A, offer three premium 2½-hour sessions dedicated to the strategic challenges reshaping the agri-food industry. Designed as genuine platforms for discussion and reflection, they will bring together experts and
UNPACK ’27: HOTELS.COM AFSLØRER DE REJSETRENDS, DER KOMMER TIL AT PRÆGE 202714.10.2026 09:00:00 CEST | Pressemeddelelse
Ny rapport fra Hotels.com identificerer fem rejsetrends, der vil komme til at præge 2027 lige fra efterspørgslen på små svipture og en genopblomstring af gotiske destinationer til næste års prognose for set-jetting. Hotels.com har i dag offentliggjort den årlige rapport Unpack ’27: The Trends in Travel™, der undersøger de destinationer, oplevelser og adfærdsmønstre, der forventes at præge rejsebranchen i 2027. Baseret på indsigter fra Hotels.com samt global rejseresearch og social listening afslører Unpack ‘27 de nye steder, der tiltrækker rejsende i 2027, og nogle overraskende ting, de foretager sig, når de først er ankommet. “At rejse handler om at skabe minder, og Unpack ‘27 afslører de destinationer og oplevelser, der præger netop de øjeblikke”, siger Ariane Gorin, CEO for Expedia Group. “I 2027 vil rejsende være mere bevidste i valget af deres næste eventyr og søge oplevelser, der er mere personlige og meningsfulde for dem. Vi gør det nemmere at opdage, planlægge og booke den rigt
Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy14.10.2026 09:00:00 CEST | Press release
Clinical evaluations demonstrated up to 51% faster fitting times for experienced clinicians and 39% improved workflow accuracy for newer clinicians; Aurical IQ also supports the NAL-NL3 Fitting System Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/ Aurical IQ Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow. A ne
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 08:29:00 CEST | Press release
Beyond vision: Neuron AI brings 3D vision, touch, audio, robot state and language together with memory in one Perception-Language-Action (PLA) model, so robots can react to what they cannot seeOne model, every body: Trained on real-world robot data, simulation-amplified data and human demonstrations, Neuron AI runs across five NEURA robot embodiments and their grippers and handsFrom skill to fleet: Customers fine-tune Neuron AI for their own tasks and deploy skills across robot fleets via the platform Neuraverse, with Time-to-Skill as the central measure of progressAI built in Germany: Developed and trained in-house in Metzingen, GermanyLive at NVIDIA GTC Berlin: NEURA’s humanoid 4NE1 will complete an eleven-minute laundry task, fully autonomous from start to finish NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom